Effects of cold stress on spleen cell proliferation and cytokine production during chronic Toxoplasma gondii infection

被引:22
作者
Aviles, H
Johnson, MT
Monroy, FP
机构
[1] No Arizona Univ, Dept Biol Sci, Flagstaff, AZ 86011 USA
[2] Morehouse Sch Med, Dept Microbiol Biochem & Immunol, Atlanta, GA 30310 USA
[3] Indiana Univ, Sch Med, Terre Haute Ctr Med Educ, Terre Haute, IN USA
关键词
immunomodulation; cold stress; spleen; proliferation; cytokine; chronic phase; Toxoplasma gondii; infection; mouse;
D O I
10.1159/000075318
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Cell-mediated immunity is critical for controlling infection and preventing reactivation during the chronic phase of Toxoplasma gondii infection. In people suffering from AIDS, T. gondii is one of the major opportunistic infectious agents. Mechanisms regulating rapid development of clinical signs in previously asymptomatic patients remain unclear; however, cofactors such as stress are suspected to play a role in the susceptibility to opportunistic infections. Objective: This study examined the role of cold stress (CS) in splenocyte function during chronic T. gondii infection. Methods: Control mice and mice previously infected orally with T. gondii were subjected to CS during the chronic phase (CSchr), i.e. 90 days after infection, and in vitro cell proliferation and cytokine production were measured before (day 0) and 1, 15 and 25 days after CSchr. Splenocyte proliferation and cytokine production were measured after in vitro stimulation with concanavalin A (Con-A), anti-CD3 antibody (A-CD3) and Toxoplasma lysate antigen. Results: CSchr enhanced splenocyte proliferation in cells stimulated with Con-A and A-CD3, but it suppressed proliferation in cells stimulated with T. gondii antigens. Increased levels of interferon (IFN)-A were detected independent of the type of stimulation after CSchr and remained high throughout the experiment. CS had similar results in noninfected animals. Conclusion: Although an overall increase in splenocyte function occurred after nonspecific stimulation, CS suppressed primed spleen cells from responding to T. gondii antigens which could lead to reactivation of latent infection. The increase in IFN-A after CSchr could be a result of spleen cells being primed by released parasites by this stressor. IFN-A is critical in the control of parasite reactivation. Copyright (C) 2004 S. Karger AG, Basel.
引用
收藏
页码:93 / 102
页数:10
相关论文
共 49 条
[11]   Low temperature enhancement of reporter genes expression directed by human immunodeficiency virus type 1 long terminal repeat [J].
ChevrierMiller, M ;
Morange, M ;
Arrigo, AP ;
Pinto, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1996, 228 (03) :695-703
[12]  
Dantzer R, 1997, ACTA PHYSIOL SCAND, V161, P43
[13]   Time course of natural killer cell activity and lymphocyte proliferation in response to two acute stressors in healthy men [J].
Delahanty, DL ;
Dougall, AL ;
Schmitz, JB ;
Hawken, L ;
Trakowski, JH ;
Jenkins, FJ ;
Baum, A .
HEALTH PSYCHOLOGY, 1996, 15 (01) :48-55
[14]   Regulation and function of T-cell-mediated immunity during Toxoplasma gondii infection [J].
Denkers, EY ;
Gazzinelli, RT .
CLINICAL MICROBIOLOGY REVIEWS, 1998, 11 (04) :569-+
[15]   Enhancing versus suppressive effects of stress hormones on skin immune function [J].
Dhabhar, FS ;
McEwen, BS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (03) :1059-1064
[16]   Stress-induced enhancement of cell-mediated immunity [J].
Dhabhar, FS .
NEUROIMMUNOMODULATION: MOLECULAR ASPECTS, INTEGRATIVE SYSTEMS, AND CLINICAL ADVANCES, 1998, 840 :359-372
[17]   Stress-induced enhancement of skin immune function:: A role for γ interferon [J].
Dhabhar, FS ;
Satoskar, AR ;
Bluethmann, H ;
David, JR ;
McEwen, BS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (06) :2846-2851
[18]   Acute stress enhances while chronic stress suppresses cell-mediated immunity in vivo: A potential role for leukocyte trafficking [J].
Dhabhar, FS ;
McEwen, BS .
BRAIN BEHAVIOR AND IMMUNITY, 1997, 11 (04) :286-306
[19]  
Elenkov IJ, 2000, PHARMACOL REV, V52, P595
[20]  
Elenkov IJ, 1996, P ASSOC AM PHYSICIAN, V108, P374